January 17, 2019. Just providing new treatment options is not enough. New treatments must provide a real tangible benefit for patients without too much risk.
Read More »On Medical Treatments & Products
NCHR Testimony at the FDA on Optimizer for Heart Failure
December 4, 2018. We all want to help these patients, but new treatments need to provide a real benefit. The questions that we need to answer are does this device help patients and should patients continue to have the option of receiving an experimental treatment as part of a clinical trial, or should they pay for an experimental treatment that has been described as a breakthrough?
Read More »Is TMS Proven Effective for Depression?
This report will examine how TMS became a frequently used treatment for depression in the United States despite what the research of the last decade shows about its very questionable effectiveness.
Read More »NCHR Testimony on Brexanolone for Postpartum Depression
November 2, 2018. We urge the committee to require more persuasive evidence on the safety of this drug. It is our moral obligation to patients to make sure that all drugs with this risk potential are scrutinized and held to a higher standard in the approval process.
Read More »NCHR Testimony on the Opioid Buprenorphine/Samidorphan for Depression
November 1, 2018. The clinical trial data do not provide adequate evidence that buprenorphine/samidorphan reduces the symptoms of depression. There are concerns about it potential for long-term harms to patients and others who might misuse or abuse it. BUP/SAM needs to provide strong evidence of efficacy before approval.
Read More »